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Abstract
The proton-coupled amino acid transporter 1 (PAT1) represents a major route by which small neutral amino acids are absorbed after intestinal
protein digestion. The system also serves as a novel route for oral drug delivery. Having shown that H+ affects affinity constants but not maximal
velocity of transport, we investigated which histidine residues are obligatory for PAT1 function. Three histidine residues are conserved among the
H+-coupled amino acid transporters PAT1 to 4 from different animal species. We individually mutated each of these histidine residues and
compared the catalytic function of the mutants with that of the wild type transporter after expression in HRPE cells. His-55 was found to be
essential for the catalytic activity of hPAT1 because the corresponding mutants H55A, H55N and H55E had no detectable L-proline transport
activity. His-93 and His-135 are less important for transport function since H93N and H135N mutations did not impair transport function. The loss
of transport function of His-55 mutants was not due to alterations in protein expression as shown both by cell surface biotinylation immunoblot
analyses and by confocal microscopy. We conclude that His-55 might be responsible for binding and translocation of H+ in the course of cellular
amino acid uptake by PAT1.
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The proton-coupled amino acid transporter 1 (PAT1) was
originally identified as the rat brain lysosomal amino acid
transport system LYAAT1, which belongs to the amino acid/
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doi:10.1016/j.bbamem.2007.12.026the transporter was isolated from mouse intestine [2] and human
Caco-2 cells [3]. The transporter was assigned to the solute
carrier (SLC) family 36 as SLC36A1 [2,3]. hPAT1 is identical to
the H+-stimulated amino acid transporter that has been des-
cribed functionally in Caco-2 cells in previous reports [4,5].
Expression of the PAT1 mRNA was detected not only in brain
and small intestine but also in liver, colon, lung, spleen and
placenta [2,3,6]. Prototype PAT1 substrates are L-proline, glycine,
β-alanine, γ-aminobutyric acid (GABA) and α-(methylamino)-
isobutyric acid (MeAIB) [2–4,6–9].
PAT1-mediated transport depends on an inwardly directed H+
gradient. H+ is co-transported with the substrates into the cell
[6,9]. The binding occurs in an ordered mechanism where H+
binds first, followed by the amino acid [10]. Transporters which
are energized by a transmembrane H+ gradient possess specific
histidine residues that are critical for their catalytic activity. The
uniqueness of the histidine residue resides in the intraprotein pKa
1043L. Metzner et al. / Biochimica et Biophysica Acta 1778 (2008) 1042–1050value of 6.7–7.1 for the imidazole group of its side chain which
is very close to the physiological pH. This characteristic renders
the histidine residues capable of easily accepting and relea-
sing H+ under physiological conditions. Thus, histidine is the
most likely amino acid residue involved in H+ binding and
translocation in H+-coupled transport systems such as the
peptide transporters PEPT1 and PEPT2, the divalent metal
transporter DMT1, the folate transporter PCFT, the organic
anion transporting polypeptide OATP2B1, the excitatory
amino acid carrier EAAC1, and others [for review see 11].
The Escherichia coli Lac permease, a prototypical H+-coupled
transport system has been extensively studied with regard to
the role of critical histidine residues in the binding and trans-
location of the cotransported H+ [12]. Diethylpyrocarbonate
(DEPC), known to block the H+ acceptor/donor function of
histidine residues of proteins by producing N-carbethoxyhisti-
dine residues, increased the apparent Km of H
+-coupled lactate
and proline transport in E. coli membrane vesicles with no
change in Vmax [12]. For the mammalian H
+-coupled di- and tri-
peptide transporter PEPT1, we have shown that both H+ and
treatment with DEPC modulate the maximal velocity of pep-
tide transport [13]. Subsequently, in site-directed mutagenesis
studies it was shown specifically that His-57 is essential for the
catalytic activity of human PEPT1 [14]. Said and Mohammad-
khani [15] observed a mixed type inhibitory effect of DEPC
on intestinal carrier-mediated folate transport. The monocarbox-
ylate transporter MCT1 is also a H+-coupled transporter and its
transport function is inhibited by DEPC; however, it appears that
histidine residues are not involved in this process because the
inhibition caused by DEPC is not reversed by hydroxylamine
[16]. Later studies by Rahman et al. have suggested that Asp-302
may be involved in H+monocarboxylate cotransport via MCT1
[17]. For hPAT1, we have demonstrated very recently that
H+ and DEPC-treatment strongly affect the affinity of the car-
rier protein for several substrates but not the maximal velocity of
L-proline transport [18]. The present investigation using site-
directed mutagenesis was performed to identify the histidine
residues that are critical for the catalytic activity of PAT1. The
hPAT1 protein consists of 476 amino acid residues, 10 of them
being histidine residues. Mutational analyses of PAT1 or the
other 3 members of the SLC36 transporter family [19] have not
yet been performed. The results of this investigation demonstrate
that His-55 is obligatory for transport in hPAT1.
2. Materials and methods
2.1. Materials
L-[3H]Proline (specific radioactivity 49 Ci/mmol) was obtained from Amer-
sham Biosciences (Little Chalfont, UK). Chemical reagents, the rabbit-anti-HA-
Tag antibody and the β-tubulin III antibody were from Sigma (Taufkirchen,
Germany). The chicken anti-hPAT1 antibody was raised against the synthetic
peptide SSTDVSPEESPSEGL by Davids Biotechnology GmbH (Regensburg,
Germany). Cell culture reagents and the secondary fluorophor-conjugated
antibody AlexaFluor®488 goat anti-rabbit IgG was purchased from Invitrogen
(Karlsruhe, Germany). The secondary anti-chicken and anti-rabbit horseradish
peroxidase conjugated antibodies were obtained from Santa Cruz Biotechnology,
Inc. (Heidelberg, Germany). The recombinant modified vaccinia virus Ankara
was provided by the GSF-Institute for Molecular Virology (Munich, Germany).2.2. Site-directed mutagenesis
The QuickChange® Site-Directed Mutagenesis Kit (Qiagen, Hilden, Ger-
many) was used to mutate the three selected histidine codons (CAC) in hPAT1
or HA-Tagged hPAT1 to an alanine codon (GCC) or an asparagine codon (AAC),
respectively, according to the manufacturer's protocol. The primers used to
mutate these histidine residues in the plasmid pSPORT1-hPAT1 were as fol-
lows: (H55A) 5′CCAGACCTTGATCGCCCTGTTAAAAGGAAACATTG3′,
(H55N) 5′GTTCCAGACCTTAATCAACCTGTTAAAAGGCAAC3′, (H55E)
5′GGTTCCAGACCCTGATCGAGCTGTTAAAAGGC3′, (H93A) 5′
CATCGTGGCCGTGGCCTGCATGGGTATCCTG3 ′ , (H93N) 5 ′
GCATCGTGGCCGTGAACTGCATGGGTATCCTGG3′, (H135A) 5′
TCCTGGCTCCGGAACGCCGCACACTGGGGAAGA3′, (H135N) 5′
TCCTGGCTCCGGAACAACGCACACTGGGGAAGA3′. The QIAprep®
Spin Miniprep Kit (Qiagen, Hilden, Germany) was used to isolate the plasmid
DNA. The specific mutations were verified by sequencing (MWG Biotech AG,
Ebersberg, Germany). For this, the primers 5′TAATACGACTCACTATAGGG'3
and 5′GGTGATTCTGACG CCTAC3′ were used.
2.3. Construction of HA-Tagged hPAT1
The DNA sequence encoding the HA-epitope was fused to the N-terminus
of the hPAT1 plasmid-cDNA by PCR. Oligo GATTGAATTCATGTATCCG-
TACGATGTTCCTGACTATGCGGGTATGTCCACGCAGAGA was the 5′
primer, oligo GTTAGCGGCCGCCTATATGAAGGCACAG the 3′ primer,
and pSPORT1-hPAT1 the template. The PCR product was cut with restriction
endonucleases EcoR I and Not I and inserted into the EcoR I/Not I digested
pSPORT1 vector. The insertion was verified by DNA sequencing and restriction
digestion by the endonucleases EcoR I and Not I.
2.4. Cell culture
Human retinal pigment epithelial (HRPE) cells (passages 8–40), maintained in
75 cm2 flasks (Sarstedt, Nümbrecht, Germany), were cultured in D-MEM/F12
supplemented with 10% fetal bovine serum (Biochrom, Berlin, Germany) and 1%
penicillin/ streptomycin (Invitrogen, Karlsruhe, Germany). Cells were released by
rinsingwith PBS and trypsination and subcultured in 75 cm2 flasks, 6-well or 24-well
plates (Sarstedt,Nümbrecht, Germany) at densities of 6×106 per flask and 1.6×106 or
0.5×106 per well.
2.5. Functional expression of hPAT1 or HA-hPAT1 in mammalian cells
HRPE cells were transiently transfected using the modified vaccinia virus
Ankara (MVA) encoding T7 RNA polymerase [3,20]. Amplification, purifica-
tion and titration of recombinant MVA to determine the amount of infectious
units per ml were performed in BHK-21 cells according to the protocol reviewed
by Staib et al. [21]. Subconfluent HRPE cells grown in 75 cm2 flasks or in 6-well
and 24-well plates were infected 22–24 h after seeding with the recombinant
MVA (50 IU/cell). At this stage the cell number that is referred to in results was
determined from control wells at a CASY®TT cell counter (Schärfe System
GmbH, Reutlingen, Germany). Next, cells were transfected with the plasmid
DNA (hPAT1, HA-hPAT1, mutant, empty vector pSPORT1) using Nanofectin®
according to manufacturers protocol (PAA Laboratories, Cölbe, Germany). The
interaction of T7 RNA polymerase with the T7 promotor located on the ex-
pression plasmids results in the overexpression of the transporter proteins in the
cells. To minimize toxic effects, medium replacement was performed 3 h after
transfection. 21 h post-transfection, uptake measurements, biotinylation, or
immunofluorescence experiments were initiated.
2.6. Uptake measurements in hPAT1 cDNA or HA-hPAT1 cDNA
transfected cells
Before the uptake experiment, cells were washed with the respective uptake
buffer. Uptake was started by incubating the cells with uptake buffer at different
pH values containing 25 mM Mes/Tris or HEPES/Tris, 140 mM NaCl, 5.4 mM
KCl, 1.8 mM CaCl2, 0.8 mM MgSO4, 5 mM glucose and 20 nM L-[
3H]proline
at room temperature. In some experiments sodium chloride was replaced by
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stopped by rinsing the monolayers four times with ice cold uptake buffer.
Samples were prepared for liquid scintillation spectrometry (Tri-Carb 2100TR,
Packard Instrument Company, Meriden, USA) by suspending the cells in 0.5 ml
lysis buffer (0.2 M NaOH, 1% SDS) and 2.8 ml scintillation cocktail. Protein
was determined according to the method of Bradford. On average, the protein
content of a well in a 24-well plate was 0.05 mg.
2.7. Cell surface biotinylation
22–24 h after seeding HRPE cells in 75 cm2 flasks (6×106 cells per flask),
cells were transfected with the empty vector pSPORT1 alone or the construct
containing the full-length hPAT1, the HA-hPAT1 or the respective mutants
cDNA. Cell-surface-expression levels were examined 21 h after transfection using
the membrane-impermeant EZ-Link® Sulfo-NHS-SS-Biotin (Pierce, Rockford,
USA). After removing the medium, cells were washed twice with ice cold PBS
containing 0.1 mM CaCl2 and 0.1 mM MgCl2 (PBS-Ca
2+/Mg2+) and then in-
cubated for 20 min at 4 °C on a shaker with EZ-Link® Sulfo-NHS-SS-Biotin
dissolved in ice-cold PBS-Ca2+/Mg2+ (1 mg/ml). Unbound biotin was quenched
after washing twice with PBS-Ca2+/Mg2+ by incubating the cells with PBS-Ca2+/
Mg2+ containing 100 mM glycine for 20–30 min at 4 °C on a shaker. Cells were
then washed three times with PBS-Ca2+/Mg2+ and scraped into this buffer, trans-
ferred into a 15 ml tube and centrifuged (400 g, 15 min). The pellet was resus-
pended in lysis buffer (150 mM NaCl, 1 mM EDTA, 100 mM Tris–HCl, 1%
Triton-X-100, 1% sodium deoxy cholate, 0.1% sodium dodecyl sulfate), con-
taining protease inhibitors (Roche Diagnostics GmbH, Mannheim, Germany),
sonicated five times and incubated in this buffer for 30 min on ice to assure total
lysis. After centrifugation (14 600 g, 4 °C, 20min), protein concentration of lysates
was determined. Protein (150–200 μg) was added to 100 μl NeutrAvidin® beads
(Pierce, Rockford, USA), incubated for 1 h at room temperature on a shaker and
then centrifuged (14 600 g, 15 min) to batch-extract biotinylated proteins. After
washing the beads four times with lysis buffer and centrifugation (14 600 g, 5 min),
boundmembrane proteins were released by incubation with 50 μl of sample buffer
(50 mM Tris–HCl, pH 6.8, 2 mM EDTA, 4% SDS, 8 M urea, 3.5% 2-mercap-
toethanol, 0.001% bromphenol blue) for 30 min on a shaker.
2.8. Western blot analyses
Lysates and cell surface proteins were separated by SDS-PAGE in 12% gels,
transferred to nitrocellulose membranes (Roth, Karlsruhe, Germany) and then
subjected to Western blot analysis. After blotting and blocking, the membranes
were incubated with the primary antibody (chicken anti-hPAT1 or rabbit anti-
HA-Tag) in TBT buffer (10 mM Tris, 150 mM NaCl, 0.2% Tween, pH 7.4)
containing 5% nonfat dry milk overnight at 4 °C on a shaker. The second
antibody (anti-chicken horseradish peroxidase-conjugated or anti-rabbit horse-
radish peroxidase-conjugated) was added after washing the membrane with TBT
buffer and the membrane was incubated for 1 h at 4 °C on a shaker. Signals were
detected using an X-ray film (Amersham, München, Germany).
2.9. Confocal laser scanning microscopy
Transfected HRPE cells were grown on coverslips in 6-well plates. Cells
were fixed and permeabilized with ice cold PBS containing 4% paraformalde-
hyde and 0.05% Triton-X-100 for 20 min. Excess of paraformaldehyde was
removed by incubation with 0.1 mM NH4Cl. After blocking with 5% bovine
serum albumin in PBS, cells were incubated for 2 h with the primary antibody
(rabbit anti-HA-Tag) diluted 1:2000 in 5% bovine serum albumin in PBS. The
second antibody (anti-rabbit AlexaFlour®488) was used in a 1:500 dilution with
an incubation time of 1 h. Nuclei were stained with DAPI (4′,6-diamidino-2-
phenylindole dihydrochloride; 1:100 in PBS). Coverslips were mounted in
CitiFlour® (Plano, Wetzlar, Germany) and samples were examined with a Nikon
ECLIPSE TE2000.
2.10. DEPC experiments
HRPE cells expressing hPAT1 or HA-hPAT1 mutants were washed twice
with buffer pH 7.5 (25 mM HEPES/Tris; containing 140 mM NaCl, 5.4 mMKCl, 1.8 mM CaCl2, 0.8 mM MgSO4, 5 mM glucose) and then incubated with
DEPC or ethanol as vehicle in buffer for 0–10 min at room temperature. The
DEPC stock solutions were prepared in ethanol before the experiment and
freshly added to each well at a final concentration of 0–1.5 mM (vehicle: 0.2%).
After the desired DEPC-incubation time, cells were washed twice and incubated
with uptake buffer pH 6.0 containing L-[H]proline (20 nM) with or without
increasing concentrations of unlabeled L-proline (0–10 mM).
2.11. Calculations and statistics
All data are given as the mean±S.E. of three to six independent experiments.
The Michaelis–Menten constant (Kt) and the maximal velocity of transport
(Vmax) were calculated by nonlinear regression of the Michaelis–Menten plot
(Sigma Plot 8.0, SPSS Inc., Chicago, USA). Statistical analysis was done by the
non-parametric two-tailed U-test and a P value of less than 0.05 was considered
statistically significant.3. Results and Discussion
3.1. Conserved histidine residues in the PAT-family
The solute carrier gene family SLC36 contains the genes
coding for the H+-coupled amino acid transporters PAT1 to 4
[2,9,19]. Mammalian PAT1 has been characterized on a mo-
lecular level in mouse, rat, rabbit, chimpanzee and human. The
sequence of PAT2 is known from mouse, rat and human. Both
PAT1 and PAT2 have been analyzed with regard to function,
localization and specificity whereas PAT3 and 4 are still orphan
transporters. The mRNA of PAT1 occurs ubiquitously but is
slightly more abundant in brain, small intestine, colon, kidney,
lung and spleen [2,3]. PAT2-mRNA has been detected in lung,
heart, kidney, muscle, testis, spleen and adrenal gland [2]. The
four SLC36 proteins consist of 470 to 504 amino acid resi-
dues with molecular weights of 53.28 kDa (hPAT1), 53.22 kDa
(hPAT2), 51.76 kDa (hPAT3) and 56.16 kDa (hPAT4) and exhibit
at least 48% identity to each other. In Fig. 1, a partial alignment
of human PAT1 to 4 and the respective PAT1 homologs in
mouse, rat and rabbit are shown. The human PAT1 protein
consists of 476 amino acid residues, 10 of them being histidine
residues. The histidine residues His-55, His-93 and His-135 in
hPAT1 are conserved both among PAT1 to 4 and the four spe-
cies. Assuming the 11 TMD topology for hPAT1, His-55 and His-
93 are located in the first and second transmembrane domain
and His-135 is located in the first intracellular loop (Fig. 1).
3.2. Functional characterization of hPAT1
Employing the vaccinia virus (MVA) expression method,
HRPE cells were used as a mammalian system for heterologous
expression of hPAT1. Cells were transiently transfected with
the cDNA of hPAT1 or the empty vector pSPORT1. Uptake of
L-[3H]proline at pH 6.0 in HRPE cells expressing hPAT1 was
linear for up to 20 min (data not shown). All further experiments
were performed using a 10 min incubation time. L-[3H]Proline
transport was first measured in uptake buffer at pH values
varying from 5.0 to 8.5. As shown in Fig. 2 (left inset), L-[3H]
proline uptake was strongly stimulated by an inwardly direct-
ed H+ gradient. At pH 7.5 and 8.5, the hPAT1-specific uptake
was barely detectable. Subsequent uptake experiments were
Fig. 1. Partial multiple sequence alignment of PAT1 proteins from human, mouse, rat, rabbit PAT1 and human PAT2 to PAT4 proteins. The alignment was performed using the
TCoffee program. (www.ch.embnet.org/software/TCoffee.html). (⁎) Identical, (.) conserved and (:) semi-conserved residues and putative transmembrane helices are designated.
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mediated transport is Na+ independent as it has been shown by
others [2–4,6,7,9], L-[3H]proline uptake in HRPE cells was
measured in the absence and presence of Na+ (Fig. 2, right
inset). The hPAT1-specific L-[3H]proline uptake in the absence
of Na+ (260±33 fmol/10 min per 400 000 cells) was not
significantly different from the uptake in the presence of Na+
(230±34 fmol/10 min per 400 000 cells). Further experiments
were performed in the presence of Na+. Under these conditions,
i.e. using a 10 min incubation at pH 6.0 in the presence of Na+,
uptake of L-[3H]proline in hPAT1 cDNA-transfected cells was
about 10 to 20 fold higher than uptake in cells transfected with
empty vector pSPORT1. Next, the substrate saturation kinetics
of L-proline uptake into hPAT1 cDNA-transfected cells was
determined by measuring uptake at increasing concentrations
of L-proline (Fig. 2). L-Proline uptake was saturable with a
Michaelis constant of 0.9±0.1 mM and a maximal transport
velocity of 8.6±0.2 nmol/10 min per 400 000 cells. These
transport properties correspond very well with previous data
on PAT mediated amino acid transport obtained at Caco-2
cells, transfected mammalian cells or Xenopus laevis oocytes
expressing PAT1 [2–4,6,7].
3.3. Generation and analysis of hPAT1 mutants
Six different mutants were generated by replacing the three
conserved histidine residues by either alanine or asparagine.
Two more mutants (double mutants) were obtained by con-
verting both of the first two conserved histidine residues, His-55
and His-93, to alanine or asparagine, respectively. The mutants
are designated as H55A, H55N, H93A, H93N, H55A/H93A,
H55N/H93N, H135A and H135N. Alanine was chosen for
mutation because of its very different properties compared tohistidine. Asparagine was selected for substitution to exclude as
far as possible local structural perturbations because replace-
ment of histidine with this amino acid would have minimal
steric effect on the resultant mutant protein. L-[3H]Proline up-
take experiments were performed in non-transfected HRPE
cells (NT) and HRPE cells transfected either with the empty
vector (pSPORT1) or the construct containing the hPAT1 or
the mutated cDNA. Compared to hPAT1, the mutants H55A,
H55N, H93A and the double mutants H55A/H93A and H55N/
H93N displayed a dramatic loss of uptake function (data not
shown, see below). Uptake by H55A and H55N mutants was 10
or 22%, respectively, compared to control. With regard to His-
93, it was observed that replacement with alanine reduced
uptake activity by 78% whereas the conversion to asparagine
reduced uptake by only 22%. Neither alanine nor asparagine
binds H+ but substitutions of histidine residues with asparagine
may cause less structural perturbations than substitutions with
alanine. There was no impact of a mutation of His-135. Both
H135A and H135N mutants transport L-[3H]proline at a rate
near control value. To rule out a pH shift effect on proline
uptake caused by the mutational changes, we measured uptake
both at pH 6.0 and 7.5. At pH 7.5 all L-[3H]proline uptake rates
were at the same low level (∼43 fmol/10 min per 400 000 cells)
and almost identical in non-transfected and transfected cells. We
concluded that mutants H55A, H55N, H93A, H55A/H93A and
H55N/H93N but not mutants H93N, H135A and H135N lost
their ability for H+-coupled L-[3H]proline transport completely.
It could be speculated that His-55 and perhaps His-93 but not
His-135 might be critical for the H+ stimulation of proline
transport by hPAT1. However, this loss of function could also
be explained by a decreased expression level of the respective
mutant in the cell membranes of HRPE cells due to instabi-
lity of mRNA, instability of protein, alterations in transporter
Fig. 2. hPAT1 cDNA-mediated L-proline uptake. Main figure: Substrate saturation kinetics of specific L-proline uptake. L-[3H]Proline uptake (20 nM; pH 6.0; 10 min,
n=4) was measured at varying concentrations of L-proline (0–10 mM) in cells transfected with either empty vector pSPORT1 as control or the construct containing the
hPAT1 cDNA. Uptake in vector-transfected cells was subtracted from uptake in hPAT1-transfected cells to calculate hPAT1-specific uptake. Left inset: Influence of
extracellular pH. L-[3H]Proline uptake (20 mM; 10 min) was determined at varying pH values, from 5.0 to 8.5. Data represent specific uptake of hPAT1 transfected
cells. Right inset: Influence of Na+ on hPAT1 transport activity. L-[3H]Proline uptake was measured in cells transfected with either vector as control or the construct
containing the hPAT1 cDNA at pH 6.0. Sodium chloride was isoosmotically replaced by choline chloride. Data are means±S.E.M., n=4.
Fig. 3. Substrate specificity of hPAT1 and HA-hPAT1. Uptake of L-[3H]proline
(20 nM) was measured in HRPE cells transfected with empty vector (pSPORT1)
as control or the plasmid containing the wildtype hPAT1 or HA-PAT1 cDNA at
pH 6 for 10 min in the presence of Na+ and unlabeled amino acids at a fixed
concentration of 5 mM. L-[3H]Proline uptake measured in the absence of
inhibitors (241±26 fmol/10 min per 400 000 cells for hPAT1 and 209±21 fmol/
10 min per 400 000 cells for HA-hPAT1) was taken as 100%. Data represent the
hPAT1 and HA-hPAT1 cDNA-specific uptake and are means±S.E.M., n=4.
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expression of hPAT1 mutants, we initiated surface protein bio-
tinylation and Western blot analyses. Immunoblot analyses with
total cell lysate of Caco-2 cells were thought to serve as positive
control for the specificity of the affinity-purified antibody raised
against a 15-amino acid synthetic peptide sequence in hPAT1.
Surprisingly, using this antibody hPAT1-like surface expression
was detected in non-transfected HRPE cells (data not shown).
From other studies we had independent evidence that the an-
tibody recognizes full length hPAT1 in Western blot analy-
ses quite specifically. But, even though there was no significant
H+-dependent L-[3H]proline uptake in these cells (Fig. 2) we
cannot rule out a very low but detectable expression of the protein.
To circumvent this problem, we used the following strategy: A
hemagglutinin (HA) epitope of 9 amino acid residueswas fused to
the N-terminus of hPAT1 cDNA. For this HA sequence, a very
specific and high-affinity monoclonal antibody is available. This
antibody could be used for the detection of HA-Tagged hPAT1,
but first we had to investigate whether hPAT1 retained its
transport properties after fusing the HA-Tag or whether this
modification impairs transport function.
3.4. Functional expression of HA-hPAT1 and mutants
L-[3H]Proline uptake measurements were repeated as descri-
bed using HRPE cells but this time transfected with HA-hPAT1
cDNA or empty vector pSPORT1. HA-hPAT1 showed identical
transport function when compared with hPAT1. HA-hPAT1
specific L-proline uptake was Na+-independent but strongly sti-
mulated in the presence of an inwardly directed H+ gradient.
Uptake was saturable with a Michaelis constant of 1.5±0.3 mMand a maximal transport velocity of 11.9±1.0 nmol/10 min per
400 000 cells (data not shown). To prove unequivocally that the
transport function of HA-hPAT1 is similar to that of hPAT1, the
substrate specificity of L-[3H]proline uptake in HRPE cells
transfected with either hPAT1 cDNA or with HA-PAT1 cDNA
was compared (Fig. 3). L-Proline and the derivatives (all 5 mM)
CHLP, CHDP and LACA showed the same inhibitory potency
in hPAT1 and HA-hPAT1 cDNA-transfected cells. The stronger
Fig. 4. Transport function of HA-hPAT1 and histidine mutants. L-[3H]Proline
uptake (20 nM; 10 min) was measured in non-transfected HRPE cells (NT) and
in cells transfected with either empty vector pSPORT1 as control or the construct
containing the HA-hPAT1 or mutant cDNA. Uptake measurements were
performed in the presence (pH 6.0) and absence (pH 7.5) of an inward-directed
H+ gradient. Data are means±S.E.M., n=4–6.
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confirms the preference of PAT1 for D-isomers of certain amino
acids. Both the PAT1 substrates glycine, GABA, L-serine, D-serine
[2,3,7] and the non-transported PAT1 inhibitor L-tryptophan [22]
displayed identical inhibition rates. L-Phenylalanine is not
transported and not recognized by the PAT1 protein. Accordingly,
we found no interaction of L-phenylalanine with either hPAT1
or HA-hPAT1.
Next, exactly as the mutational modifications of hPAT1
cDNA were done, residues His-55, His-93 and His-135 were
mutated in HA-hPAT1 cDNA to alanine or asparagine, res-
pectively. These histidine mutants are designated as HA-H55A,
HA-H55N, HA-H93A, HA-H93N, HA-H135A, HA-H135N
and HA-H55A/H93A and HA-H55N/H93N. Functional analy-
sis of HA-hPAT1 and mutants was performed using the L-[3H]
proline uptake assay at cDNA-transfected HRPE cells. Fig. 4
shows the data for HA-hPAT1- and mutant-specific uptake.
Mutations of His-55 to alanine or asparagine abolished L-[3H]
proline uptake to the level of non-transfected cells as did mu-Fig. 5. Immunoblot analysis of HA-hPAT1 and histidine mutants expressed in HRPE
with empty vector pSPORT1 as control and HA-hPAT1, HA-H55A, HA-H55N, HA-H
and cell surface proteins, separated by SDS-PAGE, were transferred onto nitrocellulo
A rabbit monoclonal anti-HA-Tag antibody was used to detect proteins isolated by
antibody was used for labeling and blots were visualized by chemiluminescence ontations to HA-H93A and double mutations HA-H55A/H93A
and HA-H55N/H93N. Conversion of His-93 to asparagine
reduced L-[3H]proline uptake by only about 36%. These results
on HA-hPAT1-HRPE are virtually identical to those obtai-
ned at hPAT1-HRPE. We also mutated HA-His-55 to gluta-
mate. Both for HA-H55E and the double mutant HA-H55E/
H93N transport activity at pH 6.0 was only 10% of wild type
(HA-hPAT1: 272±36 fmol/10 min per 400 000 cells; HA-
H55E: 28±1 fmol/10 min per 400 000 cells; HA-H55E/H93N:
26±3 fmol/10 min per 400 000 cells) uptake and equally low as
uptake into cells transfected with empty vector. We conclude
that HA-hPAT1 behaves functionally exactly as hPAT1 does.
His-55 seems to be essential for the transport function of hPAT1.
His-135 is irrelevant. His-93 does not seem to be essential for
H+ binding since mutation of this residue to asparagine does not
abolish the transport function.
3.5. Protein expression of HA-hPAT1 and mutants
To evaluate whether the loss of transport function of certain
HA-hPAT1 histidine mutants might be due to a decreased level
of protein in the plasma membrane, Western blot analyses of
biotinylated cell surface proteins were performed. In Fig. 5,
immunoblot analyses of proteins isolated from the cell surface of
non-transfected HRPE cells (NT) and HRPE cells transfected
with empty vector pSPORT1 or the construct containing the HA-
hPAT1 and the HA-hPAT1-histidine mutants cDNA are shown.
For HA-hPAT1 and the non-transporting or less-transporting
histidine mutants HA-H55A, HA-H55N, HA-H93A and HA-
H93N, their prominent expression in the plasma membrane of
HRPE cells is demonstrated. Signals for cytosolic β-tubulin III
were detected in the total cell lysate but not in the cell surface
protein fraction. We conclude that the loss of transport function
in both His-55 mutants and in the HA-H93Amutant is not due to
diminished protein expression. We confirmed this conclusion
using a second independent approach, namely immunofluores-
cence analyses by confocal laser scanning microscopy. Cells
transfected with the empty vector pSPORT1 or the construct
containing the cDNA of HA-hPAT1 or histidine mutants were
incubated with the primary rabbit anti-HA-Tag antibody followedcells. Proteins of non-transfected HRPE cells (NT) and HRPE cells transfected
93A and HA-H93N cDNAwere used for Western blot analysis. Total cell lysate
se membranes and probed with a rabbit monoclonal anti-β-tubulin III antibody.
cell surface biotinylation. A horseradish peroxidase-conjugated anti-rabbit IgG
X-ray film.
Fig. 6. Immunfluorescence localization of HA-hPAT1 and mutants in transfected HRPE cells using confocal laser scanning microscopy. Cells were transfected
with either empty vector as control or the construct containing the HA-hPAT1 and the mutant proteins HA-H55A, HA-H55N, HA-H55E, HA-H93A, HA-H93N and
HA-H55E/H93N cDNA, fixed, incubated with the primary rabbit anti-HA-Tag antibody and stained with a secondary anti-rabbit AlexaFluor®488 antibody. Nuclei
were stained with DAPI.
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stained with DAPI. As shown in Fig. 6, HA-hPAT1 and the
mutant proteins HA-H55A, HA-H55N, HA-H55E, HA-H93A,
HA-H93N and HA-H55E/H93N are localized in the plasma
membranes. Intracellular staining was observed in addition to
membrane labeling, whichmight be caused by the overexpression
of HA-hPAT1 and mutant protein. HRPE cells transfected with
empty vector pSPORT1 alone were analyzed for background-
fluorescence. No labeled cell membranes were found.
3.6. Effects of DEPC on hPAT1 and HA-hPAT1 and mutants
To obtain further evidence for the role of specific histidine
residues in H+ binding, the sensitivity of hPAT1, HA-hPAT1 and
mutants HA-H55A, HA-H93A and HA-H135A expressed in
HRPE cells to DEPC was tested. We had demonstrated that
DEPC-treatment strongly affects the affinity of hPAT1 for its
substrates but this was done using Caco-2 cells [18]. In the present
study, we first characterized the effect of DEPC on L-[3H]proline
transport in hPAT1-HRPE cells. DEPC treatment (0.3 mM) in-
hibited proline uptake completely within 5 to 10 min (Fig. 7A).
A 3 min treatment time was chosen for further experiments.
From the dose–response relationship (Fig. 7B), an IC50 value
of 0.13±0.03 mM was estimated. The influence of DEPC on
the Kt and Vmax values of L-proline uptake into hPAT1-HRPE
cells was determined in substrate saturation studies (Fig. 7C).
The Kt value of L-proline uptake, determined by linear regressionof the data shown as Eadie–Hofstee plot, was 1.9±0.3 mM in
control cells and 4.3±0.8 mM after DEPC treatment. The Vmax
values were not significantly different (8.2±1.0 nmol/10 min per
400 000 cells in control cells and 7.6±1.2 nmol/10 min per 400
000 cells after DEPC treatment, respectively). Hence, as it has
been shown in Caco-2 cells expressing hPAT1 constitutively,
treatment with DEPC at a concentration close to its IC50 value
affected only the Michaelis constant of L-proline uptake via the
cloned human PAT1. In the next series of experiments, the effect
of DEPC treatment (10 min, 0.3 mM) on L-[3H]proline transport
via HA-hPAT1 and histidine mutants was determined (Fig. 7D).
DEPC did not affect transport in mutants where hPAT1 activity
had been knocked out completely. In mutants HA-H93N and the
mutants that transport L-[3H]proline comparable to wild type
hPAT1, DEPC treatment reduced uptake by N80%.
In conclusion, our results demonstrate that His-55 is ob-
ligatory for L-proline transport via hPAT1. Western blot and
immunofluorescence analyses revealed that the loss of function
is not due to lower protein expression or integration in the cell
plasma membrane. This residue seems to be involved in binding
and translocation of H+ during the conformational change of
the protein when transporting the substrate in a cotransport
mode as it has been shown for His-57 in PEPT1 [14]. His-93
could play a role for a correct conformation of the protein in
the membrane. Besides His-55 in rat, rabbit or mouse PAT1,
other histidine residues might also be relevant (positions such
as His-12, His-103, His-104, His-137, or His-248 in hPAT1). In
Fig. 7. Effect of DEPC on the transport function of hPAT1, HA-hPAT1and mutants. A: HRPE cells expressing vector (pSPORT1) alone or hPAT1 were washed and
then incubated with DEPC (0.3 mM) or ethanol as vehicle (0.2%) in buffer (pH 7.5) for 0 to 10 min at room temperature. After the incubation time indicated, cells were
washed twice and incubated with uptake buffer pH 6.0 containing L-[3H]proline (20 nM) for 10 min. B: HRPE cells expressing hPAT1 were washed and incubated
with DEPC at different concentrations. After 3 min, cells were washed twice and incubated with uptake buffer pH 6.0 containing L-[3H]proline (20 nM) for 10 min.
C: hPAT1-HRPE cells treated for 3 min with 0.2 mM DEPC or vehicle (0.2% ethanol) were washed and incubated with buffer at pH 6.0 containing L-[3H]proline
(20 nM) and increasing concentrations of unlabeled L-proline (0–10 mM) for 10 min. Uptake in vector-transfected cells was subtracted from uptake in hPAT1-
transfected cells to calculate hPAT1-specific uptake. Results are given as Eadie–Hofstee plots. V: uptake of L-proline in nmol/10 min per 400 000 cells; S: L-proline
concentration in mM. D: HRPE cells transfected with hPAT1, HA-hPAT1 or HA-H55A, HA-H55N, HA-H93A, HA-H93N, HA-H135A and HA-H135N cDNAwere
incubated for 10 min with DEPC (0.3 mM) or ethanol as vehicle (0.2%, control) in buffer pH 7.5 at room temperature. Uptake of L-[3H]proline (20 nM) was measured
at pH 6.0 for 10 min. Data are means±S.E.M., n=4.
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the intracellular surface of the first putative transmembrane
domain. According to the 9 TMD model, His-55 would be
located in the first cytoplasmatic loop [3]. Our data indirectly
support the concept of the 11 TMD topology model.
This study represents the firstmutational analysis of amember of
the PAT-family. Because PAT1 accepts both glycine and L-proline as
substrates and because the system is expressed in intestine and
kidney, this transporter might play a key role in the human disease
iminoglycinuria [23–25]. Hence, further mutational analyses and
cell surface expression studies of hPAT1 proteins are imperative.
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